Uniform Surface Modification of 3D Bioglass(®)-Based Scaffolds with Mesoporous Silica Particles (MCM-41) for Enhancing Drug Delivery Capability.
Uniform Surface Modification of 3D Bioglass(®)-Based Scaffolds with Mesoporous Silica Particles (MCM-41) for Enhancing Drug Delivery Capability.
复制标题
DOI：
10.3389/fbioe.2015.00177
复制
发表时间：
2015
影响因子：
5.7
通讯作者：
Boccaccini AR
中科院分区：
文献类型：
--
作者：
Boccardi E;Philippart A;Juhasz-Bortuzzo JA;Beltrán AM;Novajra G;Vitale-Brovarone C;Spiecker E;Boccaccini AR
设计和表征了一种新的基于45 S5生物活性玻璃（BG）的骨组织工程和药物释放应用的多功能支架。这些基于BG的支架是通过聚氨酯包装泡沫的复制方法开发的。为了增加治疗功能，支架上涂覆了介孔二氧化硅颗粒（MCM-41），作为原位药物递送系统。这些亚微米球的特征在于大的表面积和孔体积，具有窄的孔径分布。用于合成二氧化硅介孔颗粒的溶液被设计为获得高度有序的介孔结构和球形形状-两者都是实现所需药物控释的关键因素。直接在BG基支架内合成MCM-41颗粒，并评价该组合系统的药物释放能力。此外，MCM-41颗粒涂层对BG基支架的生物活性的影响进行了评估。结果表明，它是可能的，以获得一个多功能的支架系统，其特征在于高和互连的孔隙率，高生物活性，和持续的药物输送能力。
The design and characterization of a new family of multifunctional scaffolds based on bioactive glass (BG) of 45S5 composition for bone tissue engineering and drug delivery applications are presented. These BG-based scaffolds are developed via a replication method of polyurethane packaging foam. In order to increase the therapeutic functionality, the scaffolds were coated with mesoporous silica particles (MCM-41), which act as an in situ drug delivery system. These sub-micron spheres are characterized by large surface area and pore volume with a narrow pore diameter distribution. The solution used for the synthesis of the silica mesoporous particles was designed to obtain a high-ordered mesoporous structure and spherical shape – both are key factors for achieving the desired controlled drug release. The MCM-41 particles were synthesized directly inside the BG-based scaffolds, and the drug-release capability of this combined system was evaluated. Moreover, the effect of MCM-41 particle coating on the bioactivity of the BG-based scaffolds was assessed. The results indicate that it is possible to obtain a multifunctional scaffold system characterized by high and interconnected porosity, high bioactivity, and sustained drug delivery capability.